Protein targets of acrylamide adduct formation in cultured rat dopaminergic cells

Toxicology Letters

Volumn 219, Issue 3, 2013, Pages 279-287

  Martyniuk, Christopher J ^a,c   Feswick, April ^a   Fang, Bin ^b   Koomen, John M ^b   Barber, David S ^c   Gavin, Terrence ^d   LoPachin, Richard M ^e  

^a UNIVERSITY OF NEW BRUNSWICK   (Canada)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d IONA COLLEGE   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Nerve terminal; Neurotoxicity; Protein adduct formation; Proteomic analysis; Toxic neuropathy

Indexed keywords

ACRYLAMIDE; CYSTEINE; LIPOCORTIN 1; PLECKSTRIN; PROTEOME;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CELL MEMBRANE; DIABETES MELLITUS; DOPAMINERGIC NERVE CELL; INFLAMMATION; MOLECULAR MECHANICS; NERVE CELL CULTURE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION;

ACRYLAMIDE; ANIMALS; CELLS, CULTURED; CYSTEINE; DOPAMINERGIC NEURONS; NERVE TISSUE PROTEINS; PROTEOMICS; RATS;

EID: 84877329557     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.03.031     Document Type: Article

References (33)

1. Arnold K., Bordoli L., Kopp J., Schwede T. The SWISS-MODEL Workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006, 22:195-201.
2. Bates P.A., Kelley L.A., MacCallum R.M., Sternberg M.J.E. Enhancement of protein modelling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM. Proteins: Structure Function and Genetics 2001, (Suppl. (5)):39-46.
3. Barber D.S., Stevens S., LoPachin R.M. Proteomic analysis of rat striatal synaptosomes during acrylamide intoxication at a low dose rate. Toxicological Sciences 2007, 100:156-167.
4. Barber D.S., LoPachin R.M. Proteomic analysis of acrylamide-protein adduct formation in rat brain synaptosomes. Toxicology and Applied Pharmacology 2004, 201:120-136.
5. Dalle-Donne I., Vistoli G., Gamberoni L., Giustarini D., Colmbo R., Facino R.M., Rossi R., Milzani A., Aldini G. Actin Cys374 as a nucleophilic target of α, β-unsaturated aldehydes. Free Radical Biology & Medicine 2007, 42:583-598.
6. Eliuk S.M., Renfrow M.B., Shonsey E.M., Barnes S., Kim H. Active site modifications of the brain isoform of creatine kinase by 4-hydroxy-2-nonenal correlate with reduced enzyme activity: Mapping of modified sites by Fourier transform-ion cyclotron resonance mass spectrometry. Chemical Research in Toxicology 2007, 20:1260-1268.
7. Facio F.N., Burnett A.L. Protective effect of annexin-A1 against irreversible damage to cavernous tissue after cavernous nerve injury in the rat. BJU International 2012, 110:1346-1351.
8. Frolova E.G., Pluskota E., Krukovets I., Burke T., Drumm C., Smith J.D., Blech L., Febbraio M., Bornstein P., Plow E.F., Stenina O.I. Thrombospondin-4 regulates vascular inflammation and atherogenesis. Circulation Research 2010, 107:1313-1325.
9. García-Bueno B., Madrigal J.L., Lizasoain I., Moro M.A., Lorenzo P., Leza J.C. Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biological Psychiatry 2005, 57:885-894.
10. Gerke V., Moss S.E. Annexins: from structure to function. Physiological Reviews 2002, 82(2):331-371.
11. Kisucka J., Chauhan A.K., Patten I.S., Yesilaltay A., Neumann C., Van Etten R.A., Krieger M., Wagner D.D. Peroxiredoxin1 prevents excessive endothelial activation and early atherosclerosis. Circulation Research 2008, 103:598-605.
12. Kehoe P.G., Miners S., Love S. Angiotensins in Alzheimer's disease - friend or foe?. Trends in Neurosciences 2009, 32:619-628.
13. Keller A., Nesvizhskii A.I., Kolker E., Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Analytical Chemistry 2002, 74:5383-5392.
14. Kotelnikova E., Shkrob M.A., Pyatnitskiy M.A., Ferlini A., Daraselia N. Novel approach to meta-analysis of microarray datasets reveals muscle remodeling-related drug targets and biomarkers in Duchenne muscular dystrophy. PLOS Computational Biology 2012, 8(2):e1002365.
15. Liao S., Bodmer J., Pietras D., Azhar M., Doetschman T., Schultz Jel J. Biological functions of the low and high molecular weight protein isoforms of fibroblast growth factor-2 in cardiovascular development and disease. Developmental Dynamics 2009, 238:249-264.
16. Lopachin R.M., Gavin T., Decaprio A., Barber D.S. Application of the hard and soft, acids and bases (HSAB) theory to toxicant--target interactions. Chemical Research in Toxicology 2012, 25:239-251.
17. Lopachin R.M., Gavin T. Molecular mechanism of acrylamide neurotoxicity: lessons learned from organic chemistry. Environmental Health Perspectives 2012, 120:1650-1657.
18. LoPachin R.M., Gavin T. Acrylamide-induced nerve terminal damage: relevance to neurotoxic and neurodegenerative mechanisms. Journal of Agricultural and Food Chemistry 2008, 56:5994-6003.
19. LoPachin R.M., Barber D.S., Geohagen B.C., Gavin T., He D., Das S. Structure-toxicity analysis of type-2 alkenes: in vitro neurotoxicity. Toxicological Sciences 2007, 95:136-146.
20. LoPachin R.M., Gavin T., Geohagen B.C., Das S. Neurotoxic mechanisms of electrophilic type-2 alkenes: soft-soft interactions described by quantum mechanical parameters. Toxicological Sciences 2007, 98:561-570.
21. LoPachin R.M., Barber D.S. Synaptic cysteine sulfhydryl groups as targets of electrophilic neurotoxicants. Toxicological Sciences 2006, 94:240-255.
22. LoPachin R.M., Barber D.S., He D., Das S. Acrylamide inhibits dopamine uptake in rat striatal synaptic vesicles. Toxicological Sciences 2006, 89:224-234.
23. LoPachin R.M., Schwarcz A.I., Gaughan C.L., Mansukhani S., Das S. In vivo and in vitro effects of acrylamide on synaptosomal neurotransmitter uptake and release. Neurotoxicology 2004, 25:349-363.
24. LoPachin R.M., Balaban C.D., Ross J.F. Acrylamide axonopathy revisited. Toxicology and Applied Pharmacology 2003, 188:135-153.
25. Martyniuk C.J., Alvarez S., Lo B.P., Elphick J.R., Marlatt V.L. Hepatic protein expression networks associated with masculinization in the female fathead minnow (Pimephales promelas). Journal of Proteome Research 2012, 11:4147-4161.
26. Martyniuk C.J., Fang B., Koomen J.M., Gavin T., Zhang L., Barber D.S., Lopachin R.M. Molecular mechanism of glyceraldehyde-3-phosphate dehydrogenase inactivation by α,β-unsaturated carbonyl derivatives. Chemical Research in Toxicology 2011, 24:2302-2311.
27. Mertens B., Vanderheyden P., Michotte Y., Sarre S. The role of the central renin-angiotensin system in Parkinson's disease. Journal of the Renin-Angiotensin-Aldosterone System 2010, 11:49-56.
28. Moorman W.J., Reutman S.S., Shaw P.B., Blade L.M., Marlow D., Vesper H., Clark J.C., Schrader S.M. Occupational exposure to acrylamide in closed system production plants: air levels and biomonitoring. Journal of Toxicology and Environmental Health: Part A 2012, 75:100-111.
29. Nesvizhskii A.I., Keller A., Kolker E., Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Analytical Chemistry 2003, 75:4646-4658.
30. Schwede T., Kopp J., Guex N., Peitsch M.C. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Research 2003, 31:3381-3385.
31. Seiner D.R., LaButti J.N., Gates K.S. Kinetics and mechanism of protein tyrosine phosphatase B inactivation by acrolein. Chemical Research in Toxicology 2007, 20:1315-1320.
32. Wright J.W., Harding J.W. The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases. Pflügers Archiv - European Journal of Physiology 2012, doi:10.1007/s00424-012-1102-2.
33. Yu X., Shao X.G., Sun H., Li Y.N., Yang J., Deng Y.C., Huang Y.G. Activation of cerebral peroxisome proliferator-activated receptors gamma exerts neuroprotection by inhibiting oxidative stress following pilocarpine-induced status epilepticus. Brain Research 2008, 1200:146-158.